BtoV, Wellington and Seroba co-lead $48m series-C for Quanta

This is the company's first closing for the series-C. "Quanta are talking to a blend of existing and new investors ahead of the full close of the round and commitments have already been made," said a spokesperson for the company.

The fresh capital will be used to fund the UK commercial launch of the company's lead product and a 510(k) submission to the FDA later this year. The company has not yet generated revenues.

Previous funding
In 2009, BtoV, Wellington Partners, Seroba and NBGI Ventures invested in a $14.3m series-A for the company.

Air Liquide, a gas and chemicals service, led a £27m series-B. Also participating were existing investors BtoV, Wellington, Seroba and NBGI, and new investors the Kuwait Life Sciences Company and CITA Investissement.

The company received a £1.9m grant from the National Institute for Health Research in 2015.

In 2018, MedTech Innovation Partners invested an undisclosed amount in Quanta.

Company
Quanta is focused on the commercialisation and ongoing development of its SC+ product, a cartridge-based haemodialysis system. The company was founded in 2008 as a spin-out from engineering company IMI. Based in Alcester, the company employs around 100 people.

People
BtoV – Christian Schütz (managing director).
Quanta Dialysis Technologies – John Milad (CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• UK / Ireland
• Healthcare
• Wellington Partners
• United Kingdom
• Venture